Pfizer Resumes Dosing In Phase 3 Hemophilia Gene Therapy Trial Six Months After FDA ...

Retrieved on: 2022-09-23 19:21:08

Tags for this article:

Click the tags to see associated articles and topics

Pfizer Resumes Dosing In Phase 3 Hemophilia Gene Therapy Trial Six Months After FDA .... View article details on hiswai:

Excerpt

Pfizer Inc (NASDAQ: PFE) and its partner Sangamo Therapeutics Inc (NASDAQ: SGMO) have reopened enrollment in phase 3 AFFINE study hemophilia A ...

Article found on: www.yahoo.com